New drug targets rare genetic cancers in early trial
NCT ID NCT03947385
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests a new drug called IDE196 in people with certain cancers that have specific gene mutations (GNAQ/11 or PRKC fusions), including metastatic uveal melanoma and colorectal cancer. The trial has two phases: first to find safe doses, then to see if the drug shrinks tumors. About 336 adults will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hematology Centers Western Michigan
ACTIVE_NOT_RECRUITINGGrand Rapids, Michigan, 49503, United States
-
Columbia University Medical Center - Herbert Irving Pavilion
ACTIVE_NOT_RECRUITINGNew York, New York, 10032, United States
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact
Contact Email: •••••@•••••
-
Princess Margaret Cancer Centre
ACTIVE_NOT_RECRUITINGToronto, Ontario, OPG 7-815, Canada
-
Queensland
ACTIVE_NOT_RECRUITINGWoolloongabba, 4102, Australia
-
SCRI - Denver
RECRUITINGDenver, Colorado, 80218, United States
Contact Email: •••••@•••••
Contact
-
San Francisco Oncology Associates
ACTIVE_NOT_RECRUITINGSan Francisco, California, 94115, United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
Contact
-
The Cleveland Clinic Foundation
ACTIVE_NOT_RECRUITINGCleveland, Ohio, 44195, United States
-
The Sarah Cannon Research Institute/Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-••••
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
-
UCLA Medical Center
RECRUITINGLos Angeles, California, 90095, United States
Contact Email: •••••@•••••
Contact
-
University of Cincinnati Cancer Center
RECRUITINGCincinnati, Ohio, 45267, United States
Contact Phone: •••-•••-••••
Contact
-
University of Iowa
ACTIVE_NOT_RECRUITINGIowa City, Iowa, 52242, United States
-
Westmead Hospital
ACTIVE_NOT_RECRUITINGSydney, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.